Ralf Gold

47.3k total citations · 6 hit papers
780 papers, 28.2k citations indexed

About

Ralf Gold is a scholar working on Pathology and Forensic Medicine, Neurology and Immunology. According to data from OpenAlex, Ralf Gold has authored 780 papers receiving a total of 28.2k indexed citations (citations by other indexed papers that have themselves been cited), including 324 papers in Pathology and Forensic Medicine, 278 papers in Neurology and 165 papers in Immunology. Recurrent topics in Ralf Gold's work include Multiple Sclerosis Research Studies (314 papers), Peripheral Neuropathies and Disorders (174 papers) and Polyomavirus and related diseases (95 papers). Ralf Gold is often cited by papers focused on Multiple Sclerosis Research Studies (314 papers), Peripheral Neuropathies and Disorders (174 papers) and Polyomavirus and related diseases (95 papers). Ralf Gold collaborates with scholars based in Germany, United States and Switzerland. Ralf Gold's co-authors include Ralf A. Linker, Klaus V. Toyka, Aiden Haghikia, Hans‐Peter Hartung, Kerstin Hellwig, Klaus V. Toyka, Andrew Chan, Ludwig Kappos, Hans Lassmann and Kalliopi Pitarokoili and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Ralf Gold

748 papers receiving 27.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

2012 1.3k citations Ralf Gold, Ludwig Kappos et al. profile →
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

2011 892 citations Ralf Gold et al. profile →
Spatial and temporal heterogeneity of mouse and human microglia at single-cell resolution

2019 861 citations Ralf Gold et al. profile →
Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques.

1994 623 citations Ralf Gold et al. profile →
Sex and gender issues in multiple sclerosis

2013 391 citations Ralf Gold et al. Therapeutic Advances in Neurological Disorders profile →
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

2019 308 citations Simon Faissner, Ralf Gold et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Ralf Gold	10.4k	8.1k	7.1k	6.3k	4.5k	780	28.2k
Moses Rodriguez	13.7k 1.3×	6.1k 0.8×	6.5k 0.9×	5.4k 0.9×	2.9k 0.6×	489	27.0k
Wolfgang Brück	14.7k 1.4×	6.8k 0.8×	7.1k 1.0×	7.7k 1.2×	3.4k 0.7×	391	32.1k
Tomas Olsson	14.4k 1.4×	5.5k 0.7×	10.6k 1.5×	5.8k 0.9×	4.9k 1.1×	679	31.2k
Gavin Giovannoni	14.1k 1.4×	7.2k 0.9×	4.2k 0.6×	4.3k 0.7×	4.4k 1.0×	678	26.2k
Reinhard Hohlfeld	10.0k 1.0×	6.0k 0.7×	7.6k 1.1×	5.6k 0.9×	3.2k 0.7×	301	23.0k
Amit Bar‐Or	14.5k 1.4×	5.8k 0.7×	9.1k 1.3×	5.0k 0.8×	4.0k 0.9×	453	25.9k
Heinz Wiendl	6.6k 0.6×	4.0k 0.5×	7.8k 1.1×	4.2k 0.7×	4.0k 0.9×	668	21.2k
V. Wee Yong	5.8k 0.6×	4.4k 0.5×	6.3k 0.9×	10.0k 1.6×	3.7k 0.8×	437	30.1k
Jack P. Antel	12.9k 1.2×	6.0k 0.7×	12.0k 1.7×	11.1k 1.8×	3.6k 0.8×	525	38.0k
Hans‐Peter Hartung	20.7k 2.0×	14.5k 1.8×	8.2k 1.2×	7.9k 1.3×	5.6k 1.2×	730	43.0k

Countries citing papers authored by Ralf Gold

Since Specialization

Citations

This map shows the geographic impact of Ralf Gold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ralf Gold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ralf Gold more than expected).

Fields of papers citing papers by Ralf Gold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ralf Gold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ralf Gold. The network helps show where Ralf Gold may publish in the future.

Co-authorship network of co-authors of Ralf Gold

This figure shows the co-authorship network connecting the top 25 collaborators of Ralf Gold. A scholar is included among the top collaborators of Ralf Gold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ralf Gold. Ralf Gold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aloizou, Athina‐Maria, Christoph H. Lohmann, Simon Faissner, et al.. (2025). Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis. Neurology Neuroimmunology & Neuroinflammation. 12(6). e200479–e200479. 1 indexed citations

Fisse, Anna Lena, Thomas Grüter, Christiane Schneider‐Gold, et al.. (2024). Association of the neonatal Fc receptor promoter variable number of tandem repeat polymorphism with immunoglobulin response in patients with chronic inflammatory demyelinating polyneuropathy. European Journal of Neurology. 31(4). e16205–e16205. 2 indexed citations

Schwake, Carolin, Ingo Kleiter, Bianca Teegen, et al.. (2024). Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease. Neurology Neuroimmunology & Neuroinflammation. 11(6). e200325–e200325. 2 indexed citations

Gold, Ralf, et al.. (2024). Large-fiber neuropathy in Parkinson’s disease: a narrative review. SHILAP Revista de lepidopterología. 6(1). 51–51. 1 indexed citations

Sturm, Dietrich, Nataly Stylianou, Thomas Grüter, et al.. (2024). Assessing axonal pathology and disease progression in chronic inflammatory demyelinating polyneuropathy using corneal confocal microscopy. Journal of Neurology. 272(1). 51–51.

Costa, Gloria Dalla, Letizia Leocani, Marco Pisa, et al.. (2024). Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres. Multiple Sclerosis Journal. 30(11-12). 1561–1565. 3 indexed citations

Kühn, Eva, Katharina Müller, Jeremias Motte, et al.. (2024). The association of vagal atrophy with parameters of autonomic function in multiple system atrophy and progressive supranuclear palsy. Therapeutic Advances in Neurological Disorders. 17. 4233548388–4233548388.

Grüter, Thomas, Seray Demir, Barbara Gisevius, et al.. (2023). Propionate exerts neuroprotective and neuroregenerative effects in the peripheral nervous system. Proceedings of the National Academy of Sciences. 120(4). e2216941120–e2216941120. 31 indexed citations

Richter, Daniel, et al.. (2022). Hypoechogenicity of brainstem raphe in long-COVID syndrome–less common but independently associated with depressive symptoms: a cross-sectional study. Journal of Neurology. 269(9). 4604–4610. 8 indexed citations

10.

Bartig, Dirk, Daniel Richter, Siegfried Muhlack, et al.. (2022). COVID-19 outcomes in hospitalized Parkinson’s disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany. SHILAP Revista de lepidopterología. 4(1). 27–27. 1 indexed citations

11.

Aloizou, Athina‐Maria, et al.. (2022). Mechanical Thrombectomy for Acute Ischemic Stroke in Patients with Malignancy: A Systematic Review. Journal of Clinical Medicine. 11(16). 4696–4696. 14 indexed citations

12.

Gold, Ralf, et al.. (2021). A Propagated Skeleton Approach to High Throughput Screening of Neurite Outgrowth for In Vitro Parkinson’s Disease Modelling. Cells. 10(4). 931–931. 10 indexed citations

13.

Maass, Fabian, et al.. (2019). Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson’s Disease. Cells. 8(2). 105–105. 31 indexed citations

14.

Grüter, Thomas, Wolfgang Meyer, Sven Jarius, et al.. (2019). Effects of IVIg treatment on autoantibody testing in neurological patients: marked reduction in sensitivity but reliable specificity. Journal of Neurology. 267(3). 715–720. 14 indexed citations

15.

Haghikia, Arash, Claudia Bang, Kristian Scherf, et al.. (2019). Elevated levels of miR-181c and miR-633 in the CSF of patients with MS. Neurology Neuroimmunology & Neuroinflammation. 6(6). e623–e623. 17 indexed citations

16.

Richter, Daniel, Aristeidis H. Katsanos, Christoph Schroeder, et al.. (2019). Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology. Cells. 9(1). 2–2. 27 indexed citations

17.

Pesch, Beate, Swaantje Casjens, Dirk Woitalla, et al.. (2019). Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson’s Disease. Cells. 8(2). 96–96. 28 indexed citations

18.

Bar‐Or, Amit, Douglas L. Arnold, Ralf Gold, et al.. (2012). Effects of oral BG-12 (Dimethyl Fumarate) on Magnetic Resonance Imaging (Mri) Outcomes in Relapsing-Remitting Multiple Sclerosis (Rrms): an Integrated Analysis of the Phase 3 Define and Confirm Studies. UCL Discovery (University College London). 6 indexed citations

19.

Kappos, Ludwig, D. H. Miller, David MacManus, et al.. (2006). BG00012, a novel oral fumarate, is effective in patients with relapsing-remitting multiple sclerosis. UCL Discovery (University College London). 11 indexed citations

20.

Kappos, Ludwig, D. H. Miller, David MacManus, et al.. (2006). Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a phase 2 study. UCL Discovery (University College London). 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact